Potential for trials in Russia "enormous", says ClinStar

By Gareth Macdonald

- Last updated on GMT

Related tags: Russia, Clinical trial

Russia, the Ukraine and Belarus have emerged as destinations for clinical studies and now offer “enormous” potential according to US-based CRO ClinStar.

Roger Price, director of European business development director at the contract research organisation (CRO) told Outsourcing-pharma that because fewer trials are conducted in the region there is less competition for patients than in the US.

Price also said that the legacy of the USSR's centralised system means that across the region health care provision is focused at key hubs which, he suggested, offers significant benefits in terms of both recruitment and monitoring.

He explained that: “When we do a study we can go to these hospitals, they have databases and we can access those [patients​]” and added that developing effective relationships with such institutions is critical to success in the region.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars